Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population

• Published in: Vaccine Vol. 30; no. 30; pp. 4552 - 4557
• Main Authors: Phua, Kong Boo, Lim, Fong Seng, Lau, Yu Lung, Nelson, Edmund Anthony Severn, Huang, Li Min, Quak, Seng Hock, Lee, Bee Wah, Doorn, Leen Jan van, Teoh, Yee Leong, Tang, Haiwen, Suryakiran, P.V, Smolenov, Igor V, Bock, Hans L, Han, Htay Htay
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 22-06-2012; Elsevier Limited
• Subjects: 3 years; Allergy and Immunology; Asian Continental Ancestry Group; Child, Preschool; Clinical trials; Developing countries; Diarrhea; Double-Blind Method; Efficacy; Female; Gastroenteritis; Gastroenteritis - prevention & control; Gastroenteritis - virology; Hong Kong; Hospitalization; Humans; Immunization; Industrialized nations; Infant; Infants; LDCs; Male; randomized clinical trials; RIX4414; Rotavirus; Rotavirus Infections - prevention & control; Rotavirus Vaccines - administration & dosage; Singapore; Studies; Surveillance; Taiwan; urban population; Urban populations; Vaccines; Vaccines, Attenuated - administration & dosage; Viruses; China; Singapore; Taiwan; Hong Kong; Hong Kong China; Asia; Europe; Africa; Latin America; according-to-protocol cohort; RVGE; cell culture infective dose; Rotavirus; rotavirus gastroenteritis; RIX4414; CI; Gastroenteritis; Efficacy; 3 years; CCID 50; confidence interval; ATP; CCID50; 3years
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2012.03.030

Highlights ► Efficacy results during the first three years of life and individual year follow-up periods of infants participating in this Asian study is reported. ► Efficacy against severe RVGE was 96.9% (95% CI [88.3–99.6]) over the first three years of life and 100% (67.5–100) in RIXX4414 in the third-year. ► RIX4414 was efficacious against G1 (100.0% [84.8–100]) and pooled non-G1 RV types (94.9% [80.2–99.4]).